Current share pricing gap between A2m and BAL is ridiculous, this should be closing not getting further apart. BAL SP should not even be below A2m's
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025